PURASORB PDL 45 Medical Device DL-Lactide Copolymer is a bioresorbable amorphous stereocopolymer of L-lactide and D-lactide repeat units supplied by Corbion for implantable and tissue-contact device manufacturing. The designation “PDL 45” identifies a poly(DL-lactide) grade with a nominal inherent viscosity of 0.45 dL/g measured at 0.1 g/dL in chloroform at 25 °C. The numeral in the grade name is a viscosity index rather than a molecular-weight value. The random distribution of L- and D-configurations disrupts chain regularity, suppressing crystallization; the material therefore exhibits a glass transition near 50–60 °C and no melting endotherm. This phase behavior separates PDL 45 from semi-crystalline poly(L-lactide) products, which develop crystalline lamellae during cooling and exhibit both a glass transition and a melting transition. The absence of glycolide, caprolactone, and trimethylene carbonate comonomers in PDL 45 means that the degradation rate is controlled by ester-bond hydrolysis in an amorphous polyester matrix rather than by the more rapid water uptake and acidity generation of 50:50 PLGA. Medical-device grade documentation for this product is maintained under a quality management system conforming to ISO 13485:2016, and the certificate of analysis reports residual lactide, residual solvent, tin content, and moisture content.

What Distinguishes PDL 45 from Semi-Crystalline PLLA and 50:50 PLGA in Practical Terms?

The defining difference in manufacturing is not the chemical family but the combination of amorphous phase, intermediate inherent viscosity, and absence of glycolide. PDL 45 can be processed at lower melt temperatures than semicrystalline PLLA because no crystallite melting is required; however, it also has lower stiffness and higher moisture sensitivity than oriented PLLA devices. Compared with 50:50 PLGA of similar viscosity, PDL 45 degrades more slowly and generates a less acidic local environment, but its longer degradation time may be a limitation for short-term tissue support applications. Table 1 summarizes these architecture-level differences.

The Practical Processing Window Is Defined by Moisture, Shear Heating, and Residence Time Acting Simultaneously

Pre-drying is the first critical control. Poly(DL-lactide) granules stored in sealed bags may absorb moisture to levels that cause hydrolytic chain scission during melt processing. Melt processing of PDL 45 is typically conducted after drying to a residual moisture content below 250 ppm, using a desiccant dryer with a dew point of ≤−40 °C or a vacuum oven at 70–80 °C for 8–12 h. Drying time depends on tray loading, granule size, and initial moisture; single-screw extruders and injection moulding machines should be fed with dried material through a closed conveying system to prevent rehydration. On a twin-screw extruder with an L/D ratio of 30:1, barrel settings between 180 °C and 210 °C are used. Screw speed and kneading-block configuration require particular attention because viscous dissipation can raise local melt temperature by 10–15 °C above the barrel set point, promoting random chain scission and monomer regeneration. Production-scale experience indicates that melt-pressure drift and die-face bubble formation are common failure signals when moisture is not controlled, even when barrel temperatures are unchanged. A vacuum vent at −0.08 MPa can remove volatile lactide and low-molecular-weight fragments, but it cannot compensate for inadequate pre-drying.

In injection moulding, the amorphous nature of PDL 45 avoids crystallization shrinkage, but it also lengthens solidification time in thick sections because no crystalline superstructure provides rapid modulus build-up. Melt temperatures are commonly held at 190–210 °C, with mould temperatures between 15 °C and 35 °C. Holding pressure is set according to part depth and gate geometry; typical machine settings for small medical parts fall between 600 bar and 1000 bar, but the applicable clamp force is calculated from projected area and cavity pressure rather than from these values alone. Tensile specimens machined or moulded from poly(DL-lactide) in this viscosity range have published ultimate tensile strength values near 40–55 MPa and elongation at break values below 10%; these figures are material-level results from ISO 527-2 testing and are not device specifications. The absence of a crystalline phase also means that residual stress from moulding remains distributed through the amorphous glass, so annealing below the glass transition is sometimes used to reduce stress cracking after sterilisation or during storage. Any annealing protocol must be validated because excessive time above the glass transition may cause dimensional drift without the stabilising effect of crystallites.

Sterilisation Dose Response and Hydrolytic Degradation Kinetics

Gamma irradiation of poly(DL-lactide) causes measurable reductions in molecular weight through ester-bond scission and radical-mediated oxidation. Published studies on amorphous PLA report that irradiation doses between 15 kGy and 25 kGy reduce inherent viscosity by 5–20%, with the magnitude dependent on dose rate, temperature, oxygen partial pressure, and initial molecular weight. For PDL 45, this viscosity loss is an operational boundary: if the lot is already near the lower limit of its specification, post-irradiation viscosity may fall below the value assumed in the device design file. ISO 11137-1:2006/Amd 1:2013 requires dose mapping and sterility assurance level documentation; material qualification under the same standard includes exposure to the maximum validated dose rather than only the nominal dose. Ethylene oxide sterilisation is an alternative. EtO cycles expose the polymer to moisture and moderate temperature; because amorphous PLA has finite water uptake, absorbed sterilant and water must be removed by extended aeration before the device can be released under ISO 10993-7:2008 residual limits. The selected sterilisation modality therefore interacts with both the initial viscosity specification and the intended shelf-life.

In aqueous environments, hydrolytic degradation proceeds from the surface inward for thick specimens, but in thin films and coatings water diffusion is rapid enough that bulk erosion dominates. Carboxylic acid chain ends generated by ester hydrolysis can catalyse further hydrolysis in the amorphous matrix, producing the autocatalytic behaviour common to aliphatic polyesters. The initial carboxyl end-group concentration, residual lactide content, and tin content all influence this kinetic profile. PDL 45 with residual lactide controlled to ≤0.5 wt% and residual moisture controlled to ≤0.5 wt% at release is designed to provide a more stable degradation profile than unregulated industrial PLA grades. However, the device geometry, implantation site, local pH, and mechanical load are the final determinants of mass loss; no single polymer specification can override those variables.

A Compliance Matrix for Medical-Device Use

Lot-to-lot variation in inherent viscosity within the 0.40–0.50 dL/g specification can produce measurable differences in melt pressure during extrusion, even when the barrel profile is unchanged. In production-scale twin-screw extrusion, a shift from the lower to upper viscosity limit may increase die pressure by 10–20% for a given screw speed and feed rate. Injection moulding process validation therefore should bracket both viscosity limits, not only the nominal 0.45 dL/g condition. Moisture content, residual lactide, and granule size distribution are additional batch-level variables that influence melt feeding and plasticating behaviour. Feed throat bridging can occur with small granule sizes or wide size distribution; closed conveying and nitrogen purging reduce moisture re-uptake and oxidation. Extruder barrel temperatures should be profiled with the first zone below the glass transition to avoid premature sticking and screw slippage, while downstream zones are raised to the target melt temperature. Melt pressure transducers positioned before the die provide the earliest indication of viscosity shift; a pressure rise outside the validated control band signals either moisture contamination, feed variation, or progressive chain scission caused by excessive residence time.

PDL 45 is incompatible with strong bases, primary and secondary amines, and certain organometallic nucleophiles that accelerate ester cleavage. The polymer should not be compounded with amine-containing additives or exposed to high-pH aqueous media during processing, because even low concentrations of free amine can generate rapid chain scission at melt temperatures. Transition-metal salts and residual alkoxides can also promote transesterification or discoloration; therefore, masterbatches and additives intended for implantable products must be screened for catalytic residues. In solvent-based processes, the use of protic solvents in combination with mineral acids can initiate hydrolysis before device fabrication. These incompatibilities are particularly relevant when PDL 45 is used in drug-eluting systems, because many active pharmaceutical ingredients are amine salts or carboxylic acids. Compatibility testing under ISO 10993-1:2018 and chemical interaction studies should precede compounding.

For solvent-based coatings, microparticle intermediates, and drug-eluting matrices, PDL 45 is dissolved in chlorinated or non-chlorinated solvents; solution viscosity at a given concentration is higher than for low-viscosity grades such as PDL 20 and lower than for high-viscosity PDL grades. This intermediate viscosity allows filtration through membranes with pore sizes of 0.22 µm or 0.45 µm under practical pressure limits while still yielding coherent films after solvent removal. Compared with lower-viscosity poly(DL-lactide), PDL 45 provides longer structural integrity and slower drug release in a diffusion-limited system. Compared with PLGA copolymers containing glycolide, it generates a smaller acidic degradation environment, which can be relevant for acid-labile drugs or for implants where local pH depression is a safety concern. Published data for this specific configuration are limited for every drug combination, so release-rate comparisons must be generated experimentally using the same solvent, coating thickness, drug loading, and in vitro release method. The absence of glycolide also makes PDL 45 less hydrophilic than 50:50 PLGA, which reduces initial water uptake and delays the onset of bulk erosion.

Within the PURASORB PDL product range, the numerical suffix tracks the midpoint of the inherent viscosity specification: lower-suffix grades have lower melt viscosity, faster degradation, and are used for solvent-cast or spray-dried drug delivery forms; higher-suffix grades have higher melt viscosity, better tensile strength retention, and are used for load-bearing fracture fixation devices. PDL 45 occupies the intermediate position. This is why it is selected for injection-moulded implants that must withstand short-term mechanical loading but degrade over a longer time than PLGA. The specific end-of-life profile must be confirmed in vivo, because the relationship between inherent viscosity, residual monomer content, and mass loss is nonlinear and depends on device thickness and local tissue perfusion.